Evome Medical Technologies INC 8-K filings

Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.

OTC.Pink
Evome Medical Technologies has strengthened its relationship with its senior lender, Pathward, after selling its Simbex unit and canceling a related debt extension agreement.
OTC.Pink
Evome Medical Technologies Inc. has sold its Simbex R&D business unit to EB Sports Corp., the parent company of Riddell Sports Group, for $3.55 million, aiming to reduce debt and focus on its Biodex product line.
OTC.Pink
Evome Medical Technologies reports a successful turnaround, achieving positive adjusted EBITDA for fiscal year 2023, driven by a strong fourth quarter performance.
OTC.Pink
Evome Medical Technologies has appointed Wayne Anderson and Bill Garbarini to its Board of Directors and named Kenneth Kashkin as Chairman, marking a significant step in the company's transformation.
OTC.Pink
Evome Medical Technologies has extended its Simbex acquisition debt to June 2025, increased sales targets by 7.5%, and raised Biodex product prices by 2% for 2024.
OTC.Pink
Evome Medical Technologies has reduced its acquisition debt and strengthened its management team as it prepares to launch new medical devices in 2024.
OTC.Pink
Salona Global Medical Device Corp. has changed its name to Evome Medical Technologies Inc., reflecting a new focus on innovation and growth, while also restructuring its board and reporting positive financial results.
OTC.Pink
Salona Global Medical Device Corp. has announced an exclusive distribution agreement with Veteran Medical Solutions, a company founded by a former board member who has subsequently resigned.